PredictCan Biotechnologies SAS, Biopôle Euromédecine, Grabels, France.
Contact : Céline Gongora (inserm)
"The company develops (1) innovative tools for early detection of solid tumors, and (2) cutting-edge human-derived 3D models to support drug development and precision medicine.
It is well known that Drug-induced liver injury (DILI) is a major challenge in drug development and most of the compounds that passed preclinical testing fail clinical trials because of liver toxicity. One reason of this failure is that existing preclinical models are unable to reproduce the interindividual heterogeneity of drug response in a population. PredictCan Biotechnologies SAS releases GenuineSelect-TOX, a new donor-dependent reprogramming multicellular spheroid model that recapitulates interindividual heterogeneity found in a cohort of people. Hepatic toxicity analysis revealed that the model could accurately predict clinical DILI confirmed by the FDA (FDA DILIrank). Moreover, the model could also predict chemical-induced hepatotoxicity based on host-risk factors such as age and sex. GenuineSelect-TOX is the first preclinical model that offers the possibility to (1) perform Clinical Trials-in-a-Dish for DILI, and (2) challenge DILI based on host-risk factors. At PredictCan Biotechnologies SAS, we offer an innovative solution to generate on-demand cohorts of healthy individuals for fit-on-purpose analysis of hepatotoxicity of your molecules."
Fox Biosystems
contact: martine.pugniere@inserm.fr
En bref:
La technologie SPR (Surface Plasmon Resonance) a permis de grandes avancées dans le domaine des études d’interaction mais la nécessité d’utiliser des canaux microfluidiques pour acheminer les échantillons est une limitation majeure pour certaines applications. FOx Biosystems a développé une technologie SPR basée sur des fibres optiques qui plongent directement dans les échantillons afin d’y mesurer en temps réel la fixation de protéines et autres biomolécules à leurs partenaires. Cette mise en œuvre unique de la SPR rend plus simple les applications classiques de dosage et de cinétique, mais elle rend surtout possibles de nouvelles applications : mesures d’échantillons dans des matrices complexes comme le sang total, détection de gros objets comme les vésicules extracellulaires, les virus et les phages notamment pour accélérer le phage display. L'analyse s’effectue en barrettes ou microplaques de tubes PCR, traitant jusqu'à 96 échantillons par run. Le principe de la technologie SPR par fibre optique sera expliqué, et ses applications seront discutées lors de ce séminaire.
Pour toute question, Martine Pugnière (Martine.Pugniere@inserm.fr) ou Florian Bossard, Bossard.F@foxbiosystems.com.
University of Toronto, Ontario, Canada
Contact: jean-pierre.pouget@inserm.fr
Dr. Raymond Reilly is a professor and the Director of the Centre for Pharmaceutical Oncology at the Leslie Dan Faculty of Pharmacy, University of Toronto. His research is focused on the development, preclinical evaluation and advancement to first-in-humans clinical trials of novel radiopharmaceuticals for imaging and treatment of cancer. He has published more than 180 scientific papers in this field and has trained almost 40 graduate students in the radiopharmaceutical sciences. Professor Reilly’s research is supported by the Canadian Institutes of Health Research, the Canadian Cancer Society and the Natural Sciences and Engineering Research Council of Canada. He will be speaking on his recent work to develop radiation nanomedicines for local treatment of triple-negative breast cancer and glioblastoma multiforme, the most common and lethal form of brain cancer.
Centre d'Immunologie Marseille-Luminy and Inflammation Biology, King’s College London, UK
Contact: nathalie.bonnefoy@inserm.fr
CRCT, Toulouse
contact: marie-alix.poul@inserm.fr
CRCT, Toulouse
Contact: marie-alix.poul@inserm.fr
CRCT, Toulouse
Contact IRCM : Laurent LeCam
"DDR" lab, IPBS - CNRS/Université de Toulouse
contact: Eric.julien@inserm.fr
Situé dans le Parc Euromédecine, l'Institut de Recherche en Cancérologie de Montpellier (U1194) est localisé sur le Campus Val d'Aurelle (ICM, Institut régional du Cancer Montpellier / Val d'Aurelle).
Centre de Recherche U1194 soutenu par l'Inserm, l'Université de Montpellier et l'Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de
